| Literature DB >> 34672584 |
Guillaume Mata1, Dillon H Miles1, Samuel L Drew1, Jeremy Fournier1, Kenneth V Lawson1, Artur K Mailyan1, Ehesan U Sharif1, Xuelei Yan1, Joel W Beatty1, Jesus Banuelos1, Jie Chen1, Elaine Ginn1, Ada Chen1, Kimberline Y Gerrick1, Amber T Pham1, Kent Wong1, Divyank Soni1, Puja Dhanota1, Stefan G Shaqfeh1, Cesar Meleza1, Nell Narasappa1, Hema Singh1, Xiaoning Zhao1, Lixia Jin1, Ulrike Schindler1, Matthew J Walters1, Stephen W Young1, Nigel P Walker1, Manmohan Reddy Leleti1, Jay P Powers1, Jenna L Jeffrey1.
Abstract
Phosphoinositide-3-kinase γ (PI3Kγ) is highly expressed in immune cells and promotes the production and migration of inflammatory mediators. The inhibition of PI3Kγ has been shown to repolarize the tumor immune microenvironment to a more inflammatory phenotype, thereby controlling immune suppression in cancer. Herein, we report the structure-based optimization of an early lead series of pyrazolopyrimidine isoindolinones, which culminated in the discovery of highly potent and isoform-selective PI3Kγ inhibitors with favorable drug-like properties. X-ray cocrystal structure analysis, molecular docking studies, and detailed structure-activity relationship investigations resulted in the identification of the optimal amide and isoindolinone substituents to achieve a desirable combination of potency, selectivity, and metabolic stability. Preliminary in vitro studies indicate that inhibition of PI3Kγ with compound 56 results in a significant immune response by increasing pro-inflammatory cytokine gene expression in M1 macrophages.Entities:
Mesh:
Substances:
Year: 2021 PMID: 34672584 DOI: 10.1021/acs.jmedchem.1c01153
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 7.446